Nothing Special   »   [go: up one dir, main page]

MX2023007634A - Vacuna de vector hvt multivalente. - Google Patents

Vacuna de vector hvt multivalente.

Info

Publication number
MX2023007634A
MX2023007634A MX2023007634A MX2023007634A MX2023007634A MX 2023007634 A MX2023007634 A MX 2023007634A MX 2023007634 A MX2023007634 A MX 2023007634A MX 2023007634 A MX2023007634 A MX 2023007634A MX 2023007634 A MX2023007634 A MX 2023007634A
Authority
MX
Mexico
Prior art keywords
genes
rhvt
poultry
vector vaccine
iltv
Prior art date
Application number
MX2023007634A
Other languages
English (en)
Inventor
Iwan Verstegen
Martijn Alexander Langereis
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2023007634A publication Critical patent/MX2023007634A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a nuevos constructos de HVT recombinantes (rHVT) útiles como vacuna multivalente de vectores para aves de corral. Los rHVT comprenden 4 genes heterólogos de patógenos avícolas: el gen VP2 del IBDV, el gen F del NDV y los genes gD y gI del ILTV. Los genes VP2 y F se insertan en la región del genoma Us del rHVT. Los genes gD-gl se insertan en la región del genoma UL, ya sea entre UL44 y UL45 o entre UL45 y UL46. Los nuevos rHVT demostraron ser genéticamente estables in vitro e in vivo, y expresaron todos los genes insertados lo suficientemente bien como para inducir inmunidad protectora en aves de corral vacunadas contra IBDV, NDV e ILTV.
MX2023007634A 2020-12-24 2021-12-23 Vacuna de vector hvt multivalente. MX2023007634A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20217243 2020-12-24
PCT/EP2021/087445 WO2022136623A1 (en) 2020-12-24 2021-12-23 Multivalent hvt vector vaccine

Publications (1)

Publication Number Publication Date
MX2023007634A true MX2023007634A (es) 2023-07-14

Family

ID=74003679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007634A MX2023007634A (es) 2020-12-24 2021-12-23 Vacuna de vector hvt multivalente.

Country Status (6)

Country Link
US (1) US20240058436A1 (es)
EP (1) EP4267179A1 (es)
JP (1) JP2024501943A (es)
CN (1) CN116648259A (es)
MX (1) MX2023007634A (es)
WO (1) WO2022136623A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116656630B (zh) * 2023-07-27 2023-10-20 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 重组鸭瘟病毒疫苗及其构建方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5928648A (en) 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
WO1987004463A1 (en) 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
EP0434721B1 (en) 1988-09-13 2000-03-15 Merial Viral nucleotide sequences
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
WO2012052384A1 (en) 2010-10-18 2012-04-26 Intervet International B.V. Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
US9359602B2 (en) 2011-05-26 2016-06-07 Intervet Inc. Immunostimulatory oligodeoxynucleotides
EP2714908B1 (en) 2011-05-26 2018-04-18 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
CN103890183A (zh) 2011-10-21 2014-06-25 英特维特国际股份有限公司 编码传染性喉气管炎病毒和新城疫病毒抗原的重组非致病性马立克氏病病毒构建体
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
WO2016087560A1 (en) 2014-12-04 2016-06-09 Intervet International B.V. Immortalised chicken embryo fibroblasts
AR103245A1 (es) 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
CN117357642A (zh) 2016-12-14 2024-01-09 勃林格殷格翰动物保健美国公司 表达禽病原体的多种抗原的重组hvt载体及其用途
EP3694987A1 (en) 2017-10-12 2020-08-19 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding multiple heterologous antigens
MX2020006343A (es) 2017-12-20 2020-09-03 Intervet Int Bv Diluyente mejorado para vacuna de herpesvirus alfa asociado con celulas.

Also Published As

Publication number Publication date
CN116648259A (zh) 2023-08-25
JP2024501943A (ja) 2024-01-17
US20240058436A1 (en) 2024-02-22
WO2022136623A1 (en) 2022-06-30
EP4267179A1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US11730807B2 (en) Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
EP2419132B1 (en) Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
JP3587065B2 (ja) 鳥類感染型ヘルペス属ウイルスの組み換え体、およびこれを利用した組み換えワクチン
CN104946678B (zh) 马立克氏病病毒感染性重组克隆系统及其构建方法和应用
MX2023007634A (es) Vacuna de vector hvt multivalente.
CN104031889A (zh) 表达传染性法氏囊病毒vp2蛋白的重组火鸡疱疹病毒疫苗及应用
US10758608B2 (en) Vaccine in the form of a recombinant sero type 9 avian adenovirus vector
JP6802813B2 (ja) アヒル腸炎ウイルス及びその使用
AR122653A1 (es) Vectores de hvt recombinantes que expresan hemaglutinina de influenza y composiciones inmunogénicas, su producción y usos
MX2022007579A (es) Vacuna de vector hvt multivalente.
US6410297B1 (en) Processes for preparation of Marek's disease virus using continuous avian cell lines
JPH11318447A (ja) ウイルスのヌクレオチド配列
CN109234315A (zh) 一种表达传染性法氏囊病毒vp2基因的重组火鸡疱疹病毒株
Atasoy Herpesvirus of Turkeys as a vaccine vector in viral diseases: Pros and cons
Jia et al. Current status of recombinant duck enteritis virus vector vaccine research
US20050019348A1 (en) Marek's disease virus vaccine
Mosley et al. Avian viral vector vaccines for infectious bursal disease
Woźniakowski et al. In vitro replication of recombinant Marek’S disease viruses constructed from field strains lacking meq and vtr oncogenes
BRPI1000288A2 (pt) vìrus recombinante, processo para preparar vìrus recombinante, vacina e processo de produção de vacina
MXPA99011423A (es) Procedimientos para la preparación del virus de la enfermedad de marek utilizando líneas celulares continuas de aves